- Home
- GWH vs RVPH Comparison
GWH vs RVPH Comparison
Compare GWH & RVPH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GWH
- RVPH
- Stock Information
- Founded
- GWH 2011
- RVPH 2006
- Country
- GWH United States
- RVPH United States
- Employees
- GWH N/A
- RVPH N/A
- Industry
- GWH Industrial Machinery/Components
- RVPH Biotechnology: Pharmaceutical Preparations
- Sector
- GWH Miscellaneous
- RVPH Health Care
- Exchange
- GWH Nasdaq
- RVPH Nasdaq
- Market Cap
- GWH 25.3M
- RVPH 30.1M
- IPO Year
- GWH N/A
- RVPH N/A
- Fundamental
- Price
- GWH $1.57
- RVPH $0.42
- Analyst Decision
- GWH Hold
- RVPH Strong Buy
- Analyst Count
- GWH 4
- RVPH 5
- Target Price
- GWH $2.67
- RVPH $5.20
- AVG Volume (30 Days)
- GWH 155.0K
- RVPH 1.3M
- Earning Date
- GWH 11-12-2025
- RVPH 11-13-2025
- Dividend Yield
- GWH N/A
- RVPH N/A
- EPS Growth
- GWH N/A
- RVPH N/A
- EPS
- GWH N/A
- RVPH N/A
- Revenue
- GWH $6,166,000.00
- RVPH N/A
- Revenue This Year
- GWH $131.04
- RVPH N/A
- Revenue Next Year
- GWH $76.74
- RVPH N/A
- P/E Ratio
- GWH N/A
- RVPH N/A
- Revenue Growth
- GWH N/A
- RVPH N/A
- 52 Week Low
- GWH $0.76
- RVPH $0.30
- 52 Week High
- GWH $10.12
- RVPH $4.28
- Technical
- Relative Strength Index (RSI)
- GWH 53.02
- RVPH 40.23
- Support Level
- GWH $1.36
- RVPH $0.50
- Resistance Level
- GWH $1.75
- RVPH $0.47
- Average True Range (ATR)
- GWH 0.13
- RVPH 0.03
- MACD
- GWH 0.03
- RVPH -0.01
- Stochastic Oscillator
- GWH 66.04
- RVPH 32.67
About GWH ESS Tech Inc.
ESS Tech Inc is a long-duration energy storage company specializing in iron flow battery technology. The company design and produce long-duration batteries predominantly using earth-abundant materials.
About RVPH Reviva Pharmaceuticals Holdings Inc.
Reviva Pharmaceuticals Holdings Inc is a late-stage pharmaceutical company that discovers, develops, and seeks to commercialize therapeutics for diseases. The current pipeline of the company focuses on the central nervous system, inflammatory, and cardiometabolic diseases. The company uses a chemical genomics-driven technology platform and proprietary chemistry to develop new medicines. The company's pipeline currently has two drug candidates, Brilaroxazine (RP5063) which is intended to treat multiple neuropsychiatric indications, including schizophrenia, bipolar disorder, depressive disorder, attention-deficit/hyperactivity disorder, behavioral and psychotic symptoms of dementia or Alzheimer's disease and Parkinson's disease psychosis and its other drug candidate is RP1208.